MX2024011382A - Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante. - Google Patents

Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante.

Info

Publication number
MX2024011382A
MX2024011382A MX2024011382A MX2024011382A MX2024011382A MX 2024011382 A MX2024011382 A MX 2024011382A MX 2024011382 A MX2024011382 A MX 2024011382A MX 2024011382 A MX2024011382 A MX 2024011382A MX 2024011382 A MX2024011382 A MX 2024011382A
Authority
MX
Mexico
Prior art keywords
methods
compositions
rasm
acid sphingomyelinase
recombinant human
Prior art date
Application number
MX2024011382A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Brower
Xiaoying Jin
Thomas M Wasylenko
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2024011382A publication Critical patent/MX2024011382A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024011382A 2022-03-18 2023-03-17 Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante. MX2024011382A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263321636P 2022-03-18 2022-03-18
PCT/US2023/064657 WO2023178325A1 (en) 2022-03-18 2023-03-17 Pharmaceutical recombinant human acid sphingomyelinase compositions and methods

Publications (1)

Publication Number Publication Date
MX2024011382A true MX2024011382A (es) 2024-09-23

Family

ID=86051983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011382A MX2024011382A (es) 2022-03-18 2023-03-17 Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante.

Country Status (12)

Country Link
US (1) US20230365946A1 (cg-RX-API-DMAC7.html)
EP (1) EP4493684A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509722A (cg-RX-API-DMAC7.html)
KR (1) KR20240156645A (cg-RX-API-DMAC7.html)
CN (1) CN119365593A (cg-RX-API-DMAC7.html)
AR (1) AR128825A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023235321A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254814A1 (cg-RX-API-DMAC7.html)
IL (1) IL315655A (cg-RX-API-DMAC7.html)
MX (1) MX2024011382A (cg-RX-API-DMAC7.html)
TW (1) TW202403043A (cg-RX-API-DMAC7.html)
WO (1) WO2023178325A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968454A (zh) 2022-09-28 2025-05-09 建新公司 用于生产生物产品的系统和装置及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US20020137173A1 (en) * 2001-02-05 2002-09-26 Dae-Kyong Kim Membrane-associated sphingomyelinase derived from bovine brain, isolation method therefor and anti-sphingomyelinase monoclonal anitibody
BRPI0411291A (pt) * 2003-06-12 2006-08-01 Genzyme Corp esfingomielinase acida humana modificada tendo atividade aumentada e métodos para a fabricação da mesma
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
CN101918430A (zh) 2008-01-18 2010-12-15 弗·哈夫曼-拉罗切有限公司 非糖基化蛋白质的纯化
KR20130020789A (ko) 2010-05-19 2013-02-28 에프. 호프만-라 로슈 아게 소수성 상호작용 크로마토그래피 방법
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US10259842B2 (en) 2013-05-15 2019-04-16 Medimmune, Llc Purification of recombinantly produced polypeptides
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy
EP3728287B1 (en) 2017-12-19 2024-04-10 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
PY1939780A (es) 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida

Also Published As

Publication number Publication date
TW202403043A (zh) 2024-01-16
KR20240156645A (ko) 2024-10-30
WO2023178325A1 (en) 2023-09-21
AU2023235321A1 (en) 2024-10-31
CN119365593A (zh) 2025-01-24
EP4493684A1 (en) 2025-01-22
JP2025509722A (ja) 2025-04-11
IL315655A (en) 2024-11-01
CA3254814A1 (en) 2023-09-21
US20230365946A1 (en) 2023-11-16
AR128825A1 (es) 2024-06-19

Similar Documents

Publication Publication Date Title
EP4613335A3 (en) Camptothecin compound, preparation method therefor, and application thereof
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
ZA200107110B (en) Medicament for treating diabetes.
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
WO2020198695A8 (en) Compositions, devices and methods for factor vii therapy
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE60036490D1 (de) Zusammensetzung zur behandlung von prostatakrebs
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
MY143795A (en) Tetrahydropyridoindole derivatives
HU9204029D0 (en) Proteolytic enzym inhibitors
CL2022001655A1 (es) Variantes diseñadas de la alfa-glucosidasa ácida.
TW200514772A (en) Novel tetrahydropyridine derivatives
AU2002325782A1 (en) Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation
PH12022552047A1 (en) Human alpha-galactosidase variants
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
RU2008102738A (ru) Протеазы для фармацевтического применения
MX2022008336A (es) Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21).
NZ515531A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods